Aytu Biopharma (AYTU) Gross Profit (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Gross Profit data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Gross Profit fell 40.66% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $36.7 million, a 21.37% decrease from a year earlier, with the FY2025 full-year figure at $45.8 million, down 6.57% from the prior year.
• Gross Profit for Q1 2026 stood at $7.6 million, down from $9.6 million in the prior quarter.
• Over the last five years, Gross Profit for AYTU reached as high as $18.6 million in Q2 2023 and fell as low as $7.6 million in Q1 2026.
• Historically, Gross Profit has averaged $12.7 million across 5 years, with a median of $12.7 million in 2022.
• Across the five-year window, Gross Profit soared 44.77% in 2022 and tumbled 40.66% in 2026, its largest moves.
• Year by year, Gross Profit stood at $17.3 million in 2022, then retreated by 15.56% to $14.6 million in 2023, then decreased by 26.14% to $10.8 million in 2024, then decreased by 10.77% to $9.6 million in 2025, then declined by 21.04% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $7.6 million in Q1 2026, $9.6 million in Q4 2025, and $9.2 million in Q3 2025.